Top

Published in:

01-10-2012 | EAU Guideline

Prostate cancer pain management: EAU guidelines on pain management

Authors: Pia Bader, Dieter Echtle, Valerie Fonteyne, Kostas Livadas, Gert De Meerleer, Alvaro Paez Borda, Eleni G. Papaioannou, Jan H. Vranken

Published in: World Journal of Urology | Issue 5/2012

Abstract

Context

The first publication of the European Association of Urology (EAU) guidelines on Pain Management in Urology dates back to 2003. Since then, these guidelines have been revised several times with the most recent update achieved in 2010.

Objective

Given the scope of the full text guidelines, condensing the entire document was no option in this context. This paper presents a summary of the section of pain management in prostate cancer, a topic considered of direct relevance for the practicing urologist.

Evidence acquisition

A multidisciplinary expert panel (urologists, anaesthesiologists, radio-oncologists) compiled this document based on a comprehensive consultation of the literature. Data were identified through a structured search, covering the time frame 2000 through 2010, using Medline and Embase as well as the Cochrane Library of systematic reviews. The scientific papers were weighed by the expert panel and a level of evidence (LE) assigned. Recommendations have been graded as a means to provide transparency between the underlying evidence and the guidance provided.

Evidence summary

Pain can occur in each stage of prostate cancer. It could be caused by the cancer itself (77%), be related to the cancer treatment (19%) or be unrelated to either (3%). The incidence of pain rises to 90% as patients enter the terminal phase of their illness. The physician’s task is to discover and treat the cause of pain and the pain itself, to determine whether or not the underlying cause is treatable, to provide pain relief and palliative care. These tasks more often than not require a multidisciplinary team. Pain management involves mainly pharmacotherapy, including direct anticancer therapy such as androgen deprivation and chemotherapy, as well as analgetics, for instance non-steroidal anti-inflammatory drugs (NSAIDs) or opioids. In case of local impairment due to the cancer or its metastases, primary treatments like surgery, radiotherapy or radionuclides can provide adequate pain relief. In addition, in palliative care, functional, psychosocial and spiritual support are essential components. The EAU guidelines on Pain Management in Urology are available in a number of different formats through the EAU Central Office and the EAU website (http://www.uroweb.org/guidelines/online-guidelines/).

Conclusion

The mainstay of pain management in prostate cancer is involvement of and collaboration between experts from a number of disciplines to be able to achieve a complete pain evaluation and to offer the full range of treatment options. Prostate cancer–related pain can, in most cases, be managed effectively, but it requires careful monitoring where a balance should be found between pain relief and potential side effects of treatment and quality of life (QoL).

Oxford Centre for Evidence-Based Medicine Levels of Evidence (2001) Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick, March 2009. Centre for Evidence Based Medicine Web site. http://www.cebm.net/index.aspx?o=5653. Accessed Apr 2011.

Foley KM (1979) Pain syndromes in patients with cancer. In: Bonica JJ, Ventafridda V (eds) Advances in pain research and therapy 2. Raven Press, New York, pp 59–75

Twycross RG, Lack SA (1983) Symptom control in far advanced cancer: pain relief. Pitman, London, p 6

Jensen MP (2003) The validity and reliability of pain measures in adults with cancer. J Pain 4(1):2–21PubMedCrossRef

Rosier EM, Iadarola MJ, Coghill RC (2002) Reproducibility of pain measurement and pain perception. Pain 98(1–2):205–216PubMedCrossRef

Melzack R (1975) The McGill pain questionnaire: major properties and scoring methods. Pain 1:277–299PubMedCrossRef

Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69(1–2):1–18PubMedCrossRef

Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA (1995) Validation of the world health organization guidelines for cancer pain relief: a 10-year prospective study. Pain 63:65–76PubMedCrossRef

Caraceni A, Portenoy RK (1999) An international survey of cancer pain, characteristics and syndromes. Pain 82:263–274PubMedCrossRef

10.

Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J (2008) Neuropathic pian. Redefinition and a grading system for clinical and research purposes. Neurology 70:1630–1635PubMedCrossRef

11.

Rasmussen PV, Sindrup SH, Jensen TS, Bach FW (2004) Symptoms and signs in patients with suspected neuropathic pain. Pain 110:461–469PubMedCrossRef

12.

Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau DP, Pisters LL (2003) Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170(5):1868–1871PubMedCrossRef

13.

Wilson JR, Urwin GH, Stower MJ (2005) The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl 87(1):21–24PubMedCrossRef

14.

Thompson JC, Wood J, Feuer D (2007) Prostate cancer: palliative care and pain relief. Br Med Bull 83:341–354PubMedCrossRef

15.

Ok JH, Meyers FJ, Evans CP (2005) Medical and surgical palliative care of patients with urological malignancies. J Urol 174:1177–1182PubMedCrossRef

16.

Russo P (2000) Urologic emergencies in the cancer patient. Semin Oncol 27(3):284–298PubMed

17.

Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M (2004) Members of the EORTC Genito-Urinary Group Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the “European Organization for Research and Treatment of Cancer” (EORTC) Protocol 30892. Eur Urol 45(4):457–464PubMedCrossRef

18.

McQuay HJ, Collins SL, Carroll D (2000) Radiotherapy for the palliation of painful bone metastases. Cochrane Database Sys Rev 2:CD001793

19.

Wu J, Wong R, Johnston M et al (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiot Oncol Biol Physiol 55:594–605CrossRef

20.

Sze WM, Shelley M, Held I et al (2004) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy. Cochrane Database Syst Rev 2:CD004721

21.

George R, Jeba J, Ramkumar G et al (2008) Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev 8(4):CD006716

22.

Klimo P, Thompson CJ, Kestle JRW et al (2005) A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. Neuro Oncol 7:64–76PubMedCrossRef

23.

Paes FM, Serafini AN (2010) Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 40:89–104PubMedCrossRef

24.

Krishnamurthy GT, Krishnamurthy S (2000) Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium. J Nucl Med 41(4):688–691PubMed

25.

Finlay IG, Mason MD, Shelley M (2005) Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6:392–400PubMedCrossRef

26.

Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D (1997) A dose-controlled study of 153Sm- ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33:1583–1591PubMedCrossRef

27.

Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A (2008) Giammarile. European Association of Nuclear medicine (EANM): EANM procedure guidelines for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 35(10):1934–1940PubMedCrossRef

28.

Saad H, Higano C, Sartor O, Colombel M, Murray R, Mason MD, Tubaro A, Schulman C (2006) The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 4(4):257–262PubMedCrossRef

29.

Smith MR (2005) Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 31(Suppl.3):19–25

30.

Michaelson MD, Smith MR (2005) Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23(32):8219–8224PubMedCrossRef

31.

Shih A, Jackson KC, II (2007) Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother 21(4):69–76

32.

Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M (2008) TAX-327 investigators. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14(9):2763–2767PubMedCrossRef

33.

World Health Organization (1990) Cancer pain relief and palliative Care. Report of a WHO expert committee. World Health Organization Technical Report Series, 804. Geneva, Switzerland: World Health Organization

34.

Grond S, Zech D, Schug SA, Lynch J, Lehman KA (1991) Validation of the world health organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 6(7):411–422PubMedCrossRef

35.

Maltoni M, Scarpi E, Modonesi C et al (2005) A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Supp Care Cancer 13:888–894CrossRef

36.

Miguel R (2000) Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control 7:149–156

37.

Vranken JH (2003) The palliative treatment with catheter techniques of intractable cancer pain: fourth step in the World Health Organization analgesic ladder. In: Recent Research development in Anesthesia & Analgesia. Transworld Research Network, Kerala, pp 59–71

38.

Drew J, Stambaugh JE Jr (1988) The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clin Pharmacol Ther 44(6):665–669PubMedCrossRef

39.

Fitzgerald GA (2002) Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 89(6A):26D–32D

40.

Schug SA, Sidebotham DA, Mc Guinnety M, Thomas J, Fox L (1998) Acetaminophen as an adjunct to morphine by patient-controlled analgesia in the management of acute postoperative pain. Anesth Analg 87(2):368–372PubMed

41.

Stamer UM, Stüber F (2007) Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 20(5):478–484PubMedCrossRef

42.

Hanning CD (1990) The rectal absorption of opioids. In: Benedetti C, Chapman C R, Giron G (eds) Opioid analgesia. Advances in pain research and therapy, vol 14. Raven Press, New York, pp 259–269

43.

Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K (2004) Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 20(9):1419–1428PubMedCrossRef

44.

Ahmedzai S, Brooks D (1997) Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 13(5):254–261PubMedCrossRef

45.

Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK (2001) Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 91(1–2):123–130PubMedCrossRef

46.

Saarto T, Wiffen PJ (2007) Antidepressants for neuropathic pain. Cochrane Database Syst Rev 4:CD005454

47.

Greenberg DB (1991) Strategic use of benzodiazepines in cancer patients. Oncology (Williston Park). 5(4):83–88; discussion 88, 90, 95.

48.

Caraceni A, Zecca E, Bonezzi C et al (2004) Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group. J Clin Oncol 22:2909–2917PubMedCrossRef

49.

Bell R, Eccleston C, Kalso E (2003) Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 1:CD003351

50.

Douglas I, Bush D (1999) The use of patient-controlled boluses of local anaesthetic via a psoas sheath catheter in the management of malignant pain. Pain 82:105–107PubMedCrossRef

51.

Vranken JH, van der Vegt MH, Ubags LH, Pijl AJ, Dzoljic M (2002) Continuous sacral nerve root block in the management of neuropathic cancer pain. Anesth Analg 95:1724–1725PubMedCrossRef

52.

van Dongen RT, Crul BJ, de Bock M (1993) Long-term intrathecal infusion of morphine/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain 55:119–123PubMedCrossRef

53.

van Dongen RTM, van Ee R, Crul BJP (1997) Neurologic impairment during long-term intrathecal infusion of bupivacaine in cancer patients; a sign of spinal cord compression. Pain 69:205–209PubMedCrossRef

54.

Plancarte R, de Leon Casasola OA, El Helaly M, Allende S, Lema MJ (1997) Neurolythic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth 22(6):562–568

55.

Saunders C (1987) The philosophy of terminal cancer care. Ann Acad Med Singapore 16(1):151–154PubMed

56.

Nanton V, Docherty A, Meystre C, Dale J (2009) Finding a pathway: information and uncertainty along the prostate cancer patient journey. Br J Health Psychol 14:437–458PubMedCrossRef

57.

Thaxton L, Emshoff JG, Guessous O (2005) Prostate cancer support groups: a literature review. J Psychosoc Oncol 23(1):25–40PubMedCrossRef

58.

Velthuis MJ, Agasi-Idenburg SC, Aufdemkampe G, Wittink HM (2010) The effect of physical exercise on cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials. Clin Oncol (R Coll Radiol) 22(3):208–221CrossRef

59.

Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott SG, Venner PM, Quinney HA, Jones LW, Slovinec D’Angelo ME, Wellset GA (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21:1653–1659PubMedCrossRef

Title: Prostate cancer pain management: EAU guidelines on pain management
Authors: Pia Bader
Dieter Echtle
Valerie Fonteyne
Kostas Livadas
Gert De Meerleer
Alvaro Paez Borda
Eleni G. Papaioannou
Jan H. Vranken
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 5/2012
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-012-0825-1

2024 ASCO Annual Meeting

Springer Medicine

Prostate cancer pain management: EAU guidelines on pain management

Abstract

Context

Objective

Evidence acquisition

Evidence summary

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Context

Objective

Evidence acquisition

Evidence summary

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2012

Gender-dependent cancer-specific survival following radical cystectomy

Laparoscopic radical cystectomy: initial experience using the single-incision triangulated umbilical surgery (SITUS) technique

Robot-assisted partial nephrectomy for renal tumors larger than 4 cm: results of a multicenter, international series

Individual receptor profiling as a novel tool to support diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC)

Touchless gesture user interface for interactive image visualization in urological surgery

Single-stage dorsal inlay for reconstruction of recurrent peno-glandular stenosis